This invention provides different uses of recombinant super-compoundinterferons (rSIFN-cos) and its equivalent with changed spatial configuration,high efficacy and low side effects. Therefore, high dose of rSIFN-co may beused. One characteristic of rSIFN-co is its ability to inhibit the HBV DNAduplication and secretion of HBsAg and HBeAg in in vitro pharmacologicalstudies. The cytotoxic effect of rSIFN-co is only one-eighth (1/8) ofcurrently clinically available interferons but its anti-viral effect isapproximately five to twenty (5-20) times higher, and when used in vivo it hasa broader spectrum of clinical applications and longer biofeedback response.This invention further provides super-compound interferon or its equivalent,synthesis of artificial gene with codon preference which codes for said rSIFN-co and its equivalent, vector comprising said gene and appropriate expressionsystem for expression of said rSIFN-co. Finally this invention provides thesuper-compound interferon (rSIFN-co) and its equivalent, a process to producesame and uses thereof .
